Blueprint Medicines (FRA:2L9) Beginning Cash Position : €115.2 Mil (As of Jun. 2024)

View and export this data going back to 2015. Start your Free Trial

What is Blueprint Medicines Beginning Cash Position?

Blueprint Medicines's Beginning Cash Position for the quarter that ended in Jun. 2024 was €115.2 Mil.

Blueprint Medicines's quarterly Beginning Cash Position increased from Dec. 2023 (€60.2 Mil) to Mar. 2024 (€75.0 Mil) and increased from Mar. 2024 (€75.0 Mil) to Jun. 2024 (€115.2 Mil).

Blueprint Medicines's annual Beginning Cash Position declined from Dec. 2021 (€610.5 Mil) to Dec. 2022 (€203.1 Mil) and declined from Dec. 2022 (€203.1 Mil) to Dec. 2023 (€114.5 Mil).

Blueprint Medicines Beginning Cash Position Historical Data

The historical data trend for Blueprint Medicines's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Blueprint Medicines Beginning Cash Position Chart

Blueprint Medicines Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Beginning Cash Position

Get a 7-Day Free Trial

66.09

98.32

610.48

203.07

114.54

Blueprint Medicines Quarterly Data
	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Beginning Cash Position	Get a 7-Day Free Trial															161.46	76.72	60.22	75.00	115.16

Blueprint Medicines Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

Blueprint Medicines Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of Blueprint Medicines's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Blueprint Medicines Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Blueprint Medicines Corp (FRA:2L9) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

BPMC:USA 0HOJ:UK

Address

45 Sidney Street, Cambridge, MA, USA, 02139

Website

https://www.blueprintmedicines.com

Blueprint Medicines Corp is a biopharmaceutical company. It is focused on improving the lives of patients with diseases driven by abnormal kinase activation. The company has developed a small molecule drug pipeline in cancer and a rare genetic disease. Its drug candidates BLU-285, which targets KIT Exon 17 mutants and PDGFRa D842V, abnormally active receptor tyrosine kinase mutants that are drivers of cancer and proliferative disorders. Its other drug candidate is BLU 554 FOR Advanced Hepatocellular Carcinoma, and BLU-667 for Ret Mutations, Fusions, and Predicted Resistant Mutants.

Blueprint Medicines Headlines

No Headlines